@misc{Zhou_Y-2022_89912,
title = {Clonal Hematopoiesis Is Not Significantly Associated with Covid-19 Disease Severity},
author = {Zhou, Y. and Shalhoub, R. and Rogers, S. and Yu, S. and Gu, M. and Fabre, M. and Quiros, P. and Diangson, A. and Deng, W. and Anand, S. and Lu, W. and Cullen, M. and Godfrey, A. and Preller, J. and Hadjadj, J. and Jouanguy, E. and Cobat, A. and Abel, L. and Rieux-Laucat, F. and Terrier, B. and Fischer, A. and Novik, L. and Gordon, I. and Strom, L. and Gaudinski, M. and Lisco, A. and Sereti, I. and Gniadek, T. and Biondi, A. and Bonfanti, P. and Imberti, L. and Zhang, Y. and Dalgard, C. and Dobbs, K. and Su, H. and Notarangelo, L. and Wu, C. and Openshaw, P. and Semple, M. and Mallat, Z. and Baillie, J. and Dunbar, C. and Vassiliou, G.},
month = {jul},
year = {2022},
abstract = {Clonal hematopoiesis (CH) describes the disproportionate expansion of a hematopoietic stem cell (HSC) and its progeny, in association with leukemia-associated somatic mutations, most commonly affecting the genes for epigenetic regulators DNMT3A, TET2 and ASXL1. The prevalence and size of such clones rise with age, in association with changes in the driver gene landscape.10 CH is associated with an increased risk of hematologic malignancies, but also of cardiovascular disease (CVD), independently of other known CVD risk factors.11,12 The basis for this increased CVD risk has been linked to hyperinflammatory positive feedback loops driven by increased cytokine release from clonal myeloid cells, particularly interleukin IL-6 and IL-1β.},
journal = {Blood  },
publisher = {American Society of Hematology},
url = {https://doi.org/10.1182/blood.2022015721},
}
